• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Postexposure prophylactic use of hydroxychloroquine not effective for Covid-19 prevention

byHarsh ShahandDeepti Shroff Karhade
August 8, 2020
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Prophylactic use of hydroxychloroquine within four days after exposure did not decrease cumulative incidence of coronavirus disease 2019 (Covid-19).

2. No arrhythmias or deaths occurred in the hydroxychloroquine or placebo groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19). The rapid transmission and prevalence of the virus is accelerating the evaluation of existing medications to mitigate the infection such as hydroxychloroquine. Studies on the efficacy of hydroxychloroquine against Covid-19 focus on hospitalized patients with little consideration towards its preventative properties. As such, this study evaluated the potential for hydroxychloroquine to be used as postexposure prophylaxis to prevent symptomatic infection after Covid-19 exposure. The study determined the prophylaxis use of the medication did not prevent illness compatible with Covid-19 or confirmed infections compared to the placebo control group. This randomized trial was limited by the trial design, as it enrolled patients who were younger and healthier than the group at highest risk for severe Covid-19. The difference in the participant demographics may explain the lack of reported cardiac adverse events after hydroxychloroquine use. Nonetheless, this study was strengthened by the high medication adherence among trial participants.

Click to read the study in NEJM

Relevant Reading: Association of Treatment With Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients With COVID-19 in New York State

RELATED REPORTS

Worsening kidney function observed following SARS-CoV-2 infection in children

Increased blood–urea–nitrogen-to-albumin ratio associated with increased mortality in coronavirus disease

Use of hydroxychloroquine may be protective for cardiovascular events in patients with systemic lupus erythematosus 

In-Depth [randomized controlled trial]: This randomized control trial enrolled 821 patients in a multicenter study from Canada and the United States. Participants who had household or occupational exposure to a person with confirmed Covid-19 at a distance of less than six feet for more than 10 minutes were included in this study. Participants who were younger than 18 years of age and were hospitalized were excluded. The patients were randomized in a 1:1 ratio to receive hydroxychloroquine or placebo. The primary end point was symptomatic illness confirmed by a positive molecular assay or presence of Covid-19 related symptoms. Covid-19 related symptoms included presence of cough, shortness of breath, or difficulty breathing. During the 14-day follow-up, new Covid-19 cases were confirmed for 107 of 821 participants (13.0%).  Furthermore, there was no significant difference for the incidence of new illness compatible with Covid-19 between the participants administered hydroxychloroquine (49 of 414 [11.8%]) and those administered placebo (58 of 407 [14.3%]) (P=0.35). During the trial, two hospitalizations were reported, one in each group, and no participants experienced arrhythmias or death. Upon confirmation of Covid-19 diagnosis, the most common symptoms were fatigue (49.5%), cough (44.9%), fever (34.6%), and shortness of breath (18.7%). Confirmation of Covid-19 through symptom compatibility for the illness included 48 participants (11.6%) in the hydroxychloroquine group and 55 participants (13.5%) in the control group (P=0.46). Laboratory confirmation of Covid-19 was positive for 11 participants (2.7%) in the hydroxychloroquine group and 9 participants (2.2%) in the control group (P=0.82). Taken together, postexposure prophylactic use of hydroxychloroquine did not prevent the onset of Covid-19.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: CoronavirushydroxychloroquineSARS-CoV-2
Previous Post

Further evidence that Zika virus disease associated with brain and eye birth defects

Next Post

#VisualAbstract: Clinical validity of SARS-CoV-2 antibodies

RelatedReports

Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Worsening kidney function observed following SARS-CoV-2 infection in children

May 23, 2025
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Hematology

Increased blood–urea–nitrogen-to-albumin ratio associated with increased mortality in coronavirus disease

February 10, 2025
Cardiology

Use of hydroxychloroquine may be protective for cardiovascular events in patients with systemic lupus erythematosus 

May 19, 2025
Compliance-linked incentives increase infant immunizations rates in rural India
Chronic Disease

Safety of simultaneous vs sequential mRNA COVID-19 and inactivated influenza vaccines

November 17, 2024
Next Post
#VisualAbstract: Roflumilast for chronic plaque psoriasis associated with clearer skin

#VisualAbstract: Clinical validity of SARS-CoV-2 antibodies

No survival benefit with ICDs in non-ischemic systolic heart failure: The DANISH trial

Subcutaneous ICDs noninferior to transvenous ICDs for device related complications

Compliance-linked incentives increase infant immunizations rates in rural India

mRNA-1273 SARS-CoV-2 vaccine likely effective in nonhuman primates

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.